Syndax Pharmaceuticals Inc·4

Aug 10, 6:50 AM ET

Morrison Briggs 4

4 · Syndax Pharmaceuticals Inc · Filed Aug 10, 2023

Insider Transaction Report

Form 4
Period: 2023-08-09
Morrison Briggs
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-08-09$8.77/sh+52,855$463,53870,691 total
  • Sale

    Common Stock

    2023-08-09$18.27/sh52,855$965,40217,836 total
  • Exercise/Conversion

    Stock Options (Right to buy)

    2023-08-0952,8550 total
    Exercise: $8.77From: 2027-02-06Common Stock (52,855 underlying)
Footnotes (3)
  • [F1]Following the sales reported in this Form 4, the Reporting Person has a total of 559,142 options to purchase shares of common stock that are vested and immediately exercisable and a total of 247,875 options to purchase shares of common stock that have not yet vested.
  • [F2]The sale prices ranged from $18.02 to $18.41.
  • [F3]This option is fully vested.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT